Ribavirin/Didanosine

利巴韦林/去羟肌苷

Report date: 2022/12/07 17:52:53

Base Information

Drug NameRibavirin/Didanosine

Drug Alias Name去羟肌苷/利巴韦林Didanosine/Ribavirin

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsBacterial DNA-directed RNA polymerase inhibitors +[4]

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Human immunodeficiency virus type 1 reverse transcriptaseBacterial DNA-directed RNA polymerase +[4]

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Ribavirin Didanosine

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTulane University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTulane University

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A